| The most common adverse reactions during ceftazidime treatment are local reactions following intravenous injection, allergic reactions, and effects on the gastro-intestinal tract.Local effects: Phlebitis or thrombophlebitis, and pain and/or inflammation at the site of injection.Hypersensitivity: Pruritus, rash, urticaria, erythema multiforme and fever. Toxic epidermal necrolysis and Stevens Johnson syndrome have been reported rarely. Angioedema and anaphylaxis (bronchospasm and/or hypotension) have been reported very rarely.Gastro-intestinal: Diarrhoea (diarrhoea may sometimes be a symptom of pseudomembranous colitis, see 4.4.Special warnings and special precautions for use),nausea, vomiting and abdominal pain. Very rarely, oral thrush or colitis.Central nervous system: Headache, dizziness, paraesthesiae and bad taste. There have been reports of neurological sequelae, including tremor, myoclonia, convulsions, encephalopathy and coma in patients with renal impairment in whom the dose of ceftazidime has not been appropriately reduced.Genito-urinary: Candidiasis and vaginitis.|
Blood and lymphatic system disorders (usually transient):Eosinophilia, positive Coombs' test without haemolysis, haemolytic anaemia, thrombocytosis and very rarely leucopenia, neutropenia, agranulocytosis, and thrombocytopenia.Hepatobiliary: Slight elevations in one or more hepatic enzymes: (AST (SGOT), ALT (SGPT), LDH, GGT and alkaline phosphatase), hepatitis. Very rarely, clinically apparent jaundice has been reported.Renal and urinary disorders: Elevations of blood urea, blood urea nitrogen and/or serum creatinine have been observed occasionally. Rare cases of interstitial nephritis have been reported in patients treated with ceftazidime. Acute renal tubular necrosis may occur with ceftazidime.Psychiatric disorders: Confusion and hallucinations.